Fig. 3: Swimmer plot showing patients’ disease courses, including endocrine therapy prior to trial enrollment (green), up to 12 months on combined ribociclib and endocrine therapy on the LEADER clinical protocol (blue), and follow-up after ribociclib completion (orange). | npj Breast Cancer

Fig. 3: Swimmer plot showing patients’ disease courses, including endocrine therapy prior to trial enrollment (green), up to 12 months on combined ribociclib and endocrine therapy on the LEADER clinical protocol (blue), and follow-up after ribociclib completion (orange).

From: Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

Fig. 3

Black circles indicate negative MRD test, and red circles indicated positive MRD test. Purple circles indicate metastatic recurrence, and yellow circle indicates death.

Back to article page